Corrigendum to "HIV remission trial investigators' attitudes towards risk and risk mitigation in trials that include treatment interruption" [J Virus Erad 9 (2) (June 2023) 100331].

Okumu, Eunice Akinyi; Henderson, Gail E; Golin, Carol; Kuczynski, Kriste; Ormsby, Nuchanart Q; Peay, Holly L

Okumu, Eunice Akinyi; Henderson, Gail E; Golin, Carol; Kuczynski, Kriste; Ormsby, Nuchanart Q; Peay, Holly L.

Afiliación

Okumu EA; Center for AIDS Research (CFAR), University of North Carolina at Chapel Hill, USA.
Henderson GE; Department of Social Medicine, School of Medicine, University of North Carolina at Chapel Hill, USA.
Golin C; Department of Medicine, School of Medicine, Department of Health Behavior, Gillings Global School of Public Health, University of North Carolina at Chapel Hill, USA.
Kuczynski K; Center for AIDS Research (CFAR), University of North Carolina at Chapel Hill, USA.
Ormsby NQ; Department of Social Medicine, School of Medicine, University of North Carolina at Chapel Hill, USA.
Peay HL; Department of Social Medicine, School of Medicine, University of North Carolina at Chapel Hill, USA.

J Virus Erad ; 9(3): 100340, 2023 Sep.

Article en En | MEDLINE | ID: mdl-37560051

ABSTRACT

ABSTRACT

[This corrects the article DOI 10.1016/j.jve.2023.100331.].

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Risk_factors_studies Idioma: En Revista: J Virus Erad Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google